“Our obligation to the millions suffering worldwide is to provide data-driven information. OMF recognizes this a critical moment in ME/CFS research, with the potential to galvanize efforts to effectively treat and prevent ME/CFS and other related Chronic Complex Diseases.”
Linda Tannenbaum, OMF CEO & Founder/President,
speaking at the Interagency ME/CFS Working Group Meeting.
Open Medicine Foundations’ ME/CFS and COVID-19 research project was brought into national focus at a recent, federally-sponsored meeting of the first-ever virtual Interagency ME/CFS Working Group Meeting.
This first meeting of the new Working Group focused on ME/CFS and those suffering from post-COVID-19 symptoms (aka “long-haulers”).
This meeting, unique in its scope, was the first time that representatives of multiple federal research programs met collectively with three leading ME/CFS focused nonprofits, OMF, Solve ME/CFS Initiative and #MEAction.
Hosted by the NIH and the CDC, representatives of federal research programs included:
- Three branches of the NIH
- Three branches of the CDC including the Domestic COVID Response Program
- Department of Defense: CDMRP
- Veterans Administration: Gulf War Research Program
- Department of Education: Office of Special Education Programs
- Social Security Disability Office
OMF’s CEO & Founder /President Linda Tannenbaum and OMF’s Chief Medical Officer Ron Tompkins provided an update on the OMF funded study on COVID-19’s possible conversion to ME/CFS. The presentation can be viewed here.
OMF looks for every opportunity to accelerate research. The study will examine individuals from early severe COVID-19 illness through their recovery and rehabilitation phase, offering an unprecedented chance to identify biomarkers and discover drug targets and prevention strategies for ME/CFS.
Donate your appreciated stock directly to OMF and you can receive an immediate income-tax deduction for the fair market value of the securities on the date of transfer (even if you originally paid much less for them).